Prof. David Dolphin

David Dolphin's pioneering basic research in the photochemical behaviour of porphyrin have resulted in a far-reaching understanding of these biochemically important molecules. This knowledge helped spawn the technology for Vancouver-based QLT Photo Therapeutics, which is one of the largest biotech companies in the world. Currently, he and his colleagues are developing light-activated porphyrin-based drugs which are in human clinical trials to treat a variety of hyperproliferative diseases.